Oppenheimer analyst Leah R. Cann maintained a Hold rating on Acceleron Pharma (NASDAQ: XLRN) today. The company’s shares closed yesterday at $35.99.
Cann noted:
“Acceleron’s clinical development program has expanded and existing programs remain on track. Our outlook for revenue remains unchanged. We are making very modest adjustments to operating expenses and interest income, resulting in our estimated losses per share decreasing by 2.2%, 1.7%, 0.8%, and 0.8% in years 2018 – 2021, respectively, and increasing by 1.4% in 2022.”
According to TipRanks.com, Cann is a 4-star analyst with an average return of 9.1% and a 47.9% success rate. Cann covers the Healthcare sector, focusing on stocks such as Miragen Therapeutics Inc, CytomX Therapeutics Inc, and Crispr Therapeutics AG.
Acceleron Pharma has an analyst consensus of Moderate Buy, with a price target consensus of $55.50.
See today’s analyst top recommended stocks >>
The company has a one-year high of $46.93 and a one-year low of $24.37. Currently, Acceleron Pharma has an average volume of 295.1K.
Based on the recent corporate insider activity of 39 insiders, corporate insider sentiment is neutral on the stock. Most recently, in March 2018, Tom Maniatis, a Director at XLRN bought 18,750 shares for a total of $95,250.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Acceleron Pharma, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. Its product candidates include Luspatercept, designed to patients with chronic anemia associated within a wide range of blood diseases; ACE-083, designed for the treatment of focal muscle disorders; and Sotatercept, designed to treat pulmonary arterial hypertension. The company was founded by John L. Knopf and Thomas P. Maneates in June 2003 and is headquartered in Cambridge, MA.
